Sort
10,766 grants matching “checkpoint inhibitor”
Regulation of PD-L1/PD-1 immune checkpoints by cis-interactions
$399,303Enfu Hui · University Of California, San Diego · R37 · FY2022 · CA
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
$399,250Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2022 · FD
Role of Ly6K in TGF-beta and immune escape pathways of triple negative breast cancer
$399,241Geeta Upadhyay · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2021 · CA
Shifting the immune infiltrates in osteosarcoma lung metastases with locally targeted CSF-1Ris for combination therapies
$399,187Sandro R. P. Da Rocha · Virginia Commonwealth University · R21 · FY2021 · CA
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer
$399,129Bruce E Clurman · Fred Hutchinson Cancer Research Center · R01 · FY2018 · CA
Targeting DDX3 for triple-negative breast cancer treatment
$399,129Venu Raman · Johns Hopkins University · R21 · FY2025 · CA
Role of type 2 immune response in pancreatic cancer tumorigenesis
$399,058Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
$399,051Wayne William Hancock · Children'S Hosp Of Philadelphia · R01 · FY2021 · CA
Vulnerabilities of MMR-deficient glioblastoma
$398,997Benjamin W. Purow · University Of Virginia · R01 · FY2022 · NS
Vulnerabilities of MMR-deficient glioblastoma
$398,997Benjamin W. Purow · University Of Virginia · R01 · FY2023 · NS
Novel immunotherapeutic potential of DGKalpha inhibition for glioblastoma
$398,997Benjamin W. Purow · University Of Virginia · R01 · FY2023 · NS
Vulnerabilities of MMR-deficient glioblastoma
$398,997Benjamin W. Purow · University Of Virginia · R01 · FY2025 · NS
Tumor Suppressor Qualities and Mechanisms of LZAP Activity
$398,899Wendell G Yarbrough · Yale University · R01 · FY2013 · DE
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice
$398,871Joseph C. Glorioso · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
Highly stable mini-circRNA vaccine with maximally activated and long-lasting T cells for HPV-related cancer combination immunotherapy
$398,823Gordon Parry · Ampedrna Biosciences Llc · R43 · FY2024 · CA
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
$398,787Shweta Joshi · University Of California, San Diego · R01 · FY2025 · NS
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
$398,787Shweta Joshi · University Of California, San Diego · R01 · FY2022 · NS
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
$398,787Shweta Joshi · University Of California, San Diego · R01 · FY2023 · NS
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
$398,787Shweta Joshi · University Of California, San Diego · R01 · FY2021 · NS
A Dual Action Antibody Drug Conjugate to Treat Triple Negative Breast Cancer by Enhancing Tumor Immunity
$398,734Reiner Laus · Trio Pharmaceuticals Inc. · R43 · FY2022 · CA
Role of Ly6K in TGF-beta and immune escape pathways of triple negative breast cancer
$398,541Geeta Upadhyay · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2020 · CA
Pathways that integrate cell growth with the cell cycle
$398,465Douglas R. Kellogg · University Of California Santa Cruz · R01 · FY2010 · GM
Controlling HIV latency by manipulating CycT1 turnover
$398,360Koh Fujinaga · University Of California, San Francisco · R01 · FY2023 · AI
Controlling HIV latency by manipulating CycT1 turnover
$398,360Koh Fujinaga · University Of California, San Francisco · R01 · FY2024 · AI
Controlling HIV latency by manipulating CycT1 turnover
$398,360Koh Fujinaga · University Of California, San Francisco · R01 · FY2025 · AI